Study on dose-effect relationship of nasal remimazolam for preoperative pediatric sedation

Study on dose-effect relationship of intranasal esmketamine or remimazolam for preoperative pediatric sedation and the superiority of remimazolam

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059493

Enrollment

Unknown

Registered

2022-05-02

Start date

2022-04-20

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric preoperative anxiety

Interventions

Group 1 :nasal administration of remimazolam

Eligibility

Sex/Gender

All

Age

2 Years to 6 Years

Inclusion criteria

Inclusion criteria: 1. 2-6 years old; 2. ASA I or II grade; 3. BMI 15-20 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Upper respiratory tract infection; 2. Runny nose or nasal secretions; 3. Sleep apnea syndrome; 4. Remimazolam allergy; 5. Severe systemic diseases.

Design outcomes

Primary

Measure	Time frame
Ramsay sedation score;	—

Secondary

Measure	Time frame
Blood pressure;Heart rate;m-YPAS score;Blood oxygen saturation;Adverse effect;	—

Countries

China

Contacts

Public ContactYuan Kaiming

The Second Affiliated Hospital of Wenzhou Medical University

117339446@qq.com+86 13819708274

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026